Some authors hypothesize that DPP4 inhibitors could represent a new strategy to support the treatment of COVID-19 in patients, with or without diabetes, by reducing the viral entry and replication into the respiratory tract and by hampering the inflammation and cytokine storm within the lungs [47]. Here, DPP4 is linked to diabetes mellitus.